Are Patients Being Injured With Testosterone Therapy While Companies Make Millions in Profits?

FREE CASE EVALUATION: CALL 1-800-632-1404

You may be visiting this website because you or a loved one has experienced a testosterone replacement injury including a testosterone stroke, a testosterone heart attack or a testosterone blood clot. If so, please keep reading.

In the opinion of some, large businesses have turned testosterone-boosting drugs into a $2 billion marke. In a new study in the Journal of the American Medical Association there are concerns over Low T therapy: it may cause cardiovascular events such as heart attacks, blood clots, strokes and pulmonary embolism. These would result in a low testosterone injury.

Over the past couple of years, therapies such as Eli Lilly’s Axiron; AbbVie’s AndroGel; and Auxilium and GlaxoSmithKline’s Testim have taken off like a rocket as companies rolled out new products and amped up their advertising. IMS Health says sales of testosterone drugs grew by 90% over 5 years, reaching $1.9 billion in 2011. By 2017, the entire testosterone market is expected to hit $5 billion.

Researchers analyzed the medical records of 8,709 male veterans with low testosterone who had a coronary angiogram. Of that group, 1,223 men began testosterone therapy after their procedure. The rate of death, heart attack or stroke hit 25.7% in that group, compared with 19.9% in the men who didn’t use testosterone drugs

After controlling for various factors, the researchers calculated a 29% increase in risk for the men who used testosterone. And as Forbes points out, the change in risk was the same in men who had coronary artery disease as in men who didn’t–and the testosterone group had a lower risk profile to begin with. The research isn’t conclusive; as an observational study, it’s more of a flag for future study than a clear warning. A JAMA editorial points out that the analysis includes little information about whether the drugs were prescribed according to label guidelines. But the editorial also advises caution. The number of prescriptions is growing quickly, and drugmakers continue to aggressively advertise the treatments. As the editorial points out, some men are using testosterone for lifestyle reasons, rather than to replace actual, clinical deficits in their hormone levels–for antiaging and “physical enhancement,” for instance, JAMA notes. Does any increase in risk apply to these younger, perhaps healthier, men?

Here’s where pharma advertising comes in. Earlier this year, Consumer Reports urged men to be wary about starting hormone therapy, saying most men really don’t need the drugs. The magazine cited drugmakers’ big-time spending on marketing the products, with promotional expenses up to $100 million in 2012 from $14 million in 2011. For 2013, that figure may grow substantially. For the first half of this year alone, AbbVie spent more than $45 million promoting Androgel, which is now its second-best-selling drug. Still, AbbVie, Lilly and other drugmakers say they only market their testosterone products for men whose hormone levels are clinically low. For now, the data on testosterone use is far from comprehensive. A National Institutes of Health study is set to wrap up next year. In the meantime, the JAMA researchers say their study at least offers some perspective. “Prior to this study, we didn’t know much about the cardiovascular risk,” said lead author Michael Ho, a cardiologist with the Veterans Affairs Eastern Colorado Health Care System.

If you or a loved one have experienced a testosterone replacement therapy injury after undergoing low testosterone therapy, please contact our team of lawyers today for a free case evaluation at:

CALL: 1-800-632-1404

FILL OUT THIS FORM FOR A FREE CONSULTATION AND CASE EVALUATION:

Your Name (required)

Your Email (required)

Your Phone Number (required)

Case Details

1+1=?

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

September 30, 2011

Mesothelioma Lawyers in Tennessee

Mesothelioma is a rare form of lung cancer with the only known cause to be exposure to Asbestos. Typically, those of us experienced in Asbestos disease litigation have seen high rates of Mesothelioma among construction and shipyard workers. With the passing of workers with direct of exposure, however, a disturbing trend is emerging. Recently, the trend is to see Mesothelioma in people of ages below 40. These people are known to have no direct exposure to Asbestos, but with a little digging, it can be determined that a father or grandfather did indeed have direct Asbestos exposure. These younger people developing the dreaded disease are those thought to have what is known as “secondary exposure.” Much like children of smokers have secondary exposure to smoke which can cause cancer, these Mesothelioma victims are known to have had contact with a parent/grandparent who brought Asbestos home on clothing from occupational exposure. While Asbestos has been off of the market now for almost 40 years, at least in the United States, it is expected that cases of Mesothelioma will still continue to show up in the younger generations due to this secondary exposure.

If you have been diagnosed with Mesothelioma, please call us today at 1-800-632-1404. We will provide you with immediate personal representation.

February 24, 2011

Triad Alcohol Pad Worldwide Recall

FREE CASE EVALUATIONS – CALL 1-800-632-1404

The FDA has reported a worldwide recall of Triad Alcohol Pads:

FOR IMMEDIATE RELEASE – January 5, 2011 – Hartland, Wisconsin, Triad Group, a manufacturer of over-the-counter products has initiated a voluntary product recall involving ALL LOTS of ALCOHOL PREP PADS, ALCOHOL SWABS, and ALCOHOL SWABSTICKS manufactured by Triad Group but which are private labeled for many accounts to the consumer level. This recall involves those products marked as STERILE as well as non-sterile products. This recall has been initiated due to concerns from a customer about potential contamination of the products with an objectionable organism, namely Bacillus cereus. We are, out of an abundance of caution, recalling these lots to ensure that we are not the source of these contamination issues.

Use of contaminated Alcohol Prep Pads, Alcohol Swabs or Alcohol Swabsticks could lead to life-threatening infections, especially in at risk populations, including immune suppressed and surgical patients. To date we have received one report of a non-life-threatening skin infection.

Alcohol Prep Pads, Alcohol Swabs and Alcohol Swabsticks are used to disinfect prior to an injection. They were distributed nationwide to retail pharmacies and are packaged in individual packets and sold in retail pharmacies in a box of 100 packets. The affected Alcohol Prep Pads, Alcohol Swabs and Alcohol Swabsticks can be identified by either “Triad Group,” listed as the manufacturer, or the products are manufactured for a third party and use the names listed below in their packaging:

Cardinal Health
PSS Select
VersaPro
Boca/ Ultilet
Moore Medical
Walgreens
CVS
Conzellin

These products were distributed in the United States, Canada and Europe.

Specific customers distributing the product and selling it at the wholesale, hospital and retail pharmacy level have been notified by certified mail with instructions on how to return the product. If a consumer has any of these types of products in their possession listing “Triad Group” as the manufacturer, they should not use the product and should return it to the place it was purchased for a full refund or call Triad Group Customer Service Monday through Friday between the hours of 8:30 A.M. and 4:00 P.M. Central Time: 262.538.2900.

DO NOT RETURN THE PRODUCT ON YOUR OWN, simply call the Triad Group Customer Service listed below and we will issue you a return authorization number and make all return arrangements.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online:http://www.fda.gov/MedWatch/report.htm¹
Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: http://www.fda.gov/MedWatch/getforms.htm² Mail to address on the pre-addressed form.
Fax: 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food & Drug Administration

Ed Wallis is an attorney currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Wellbutrin, Paxil, Avandia, Accutane and Reglan. He also represents clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k cochlear implant and the Gynecare Prolift transvaginal mesh – sling and the DePuy hip implant. In fact, Mr. Wallis serves as counsel to persons around the world for defective medical devices and drugs. He and other members of the firm are willing to discuss a Triad injury today.

For a free case evaluation and to immediately discuss the facts of your potential claim, please contact us before your time to act runs out:

TOLL FREE: 1-800-632-1404

CALL: (901) 527-2125

EMAIL: click here

FILL OUT THIS FORM:

Your Name (required)

Your Email (required)

Your Telephone Number

What year was your child born?

Where do you live (state)?

February 24, 2011

Triad Alcohol Pad Injury Help

FREE CASE EVALUATIONS – CALL 1-800-632-1404

A Tennessee man has filed a $50 million lawsuit for permanent injuries he alleges were caused by defective Triad alcohol prep pads, manufactured by Triad Group. Our firm is offering free case evaluations to anyone that was affected by allegedly defective Triad Alcohol Prep Pads. Triad is owned and/or operated by H&P Industries.

Triad Group has issued a voluntary worldwide recall on its alcohol prep pads. You can view the FDA recall by CLICKING HERE. Triad’s recall covers all lots of its alcohol prep pads, wipes and swabs, totaling perhaps hundreds of millions of products sold in the U.S., Canada and Europe.

MSNBC has reported that FDA Form 483’s confirm numerous observational violations by Triad Group in the manufacture of Triad Alcohol Prep Pads. The FDA Form 483’s were received via a confidential source. It is expected that additional lawsuits will be filed on behalf of those injured by a Triad Alcohol Prep Pad, and if you would like more information about a Triad lawsuit or would like to speak to a Triad lawyer about a potential Triad class action case or a Triad individual lawsuit, call us today.

Our firm represents children and adults around the globe after receiving allegeldy defective and harmful medical devices and prescription drugs. This would include persons affected by the more than 100 reports of problems with alcohol prep pads which have been logged by the FDA since the Jan. 5 recall of Triad products because of potential contamination with the bacteria Bacillus cereus, an agency spokesman said.

For a free case evaluation and to immediately discuss the facts of your potential claim, please contact us before your time to act runs out:

TOLL FREE: 1-800-632-1404

CALL: (901) 527-2125

EMAIL: click here

FILL OUT THIS FORM:

Your Name (required)

Your Email (required)

Your Telephone Number

What year was your child born?

Where do you live (state)?

October 6, 2008

More Claims Added to Nursing Home Suit

A group of Washington state nursing homes took on patients they could not properly care for in order to increase profits, according to a recently expanded lawsuit. In the lawsuit, plaintiffs allege that the homes, run by Milwaukee-based Extendicare Health Services, violated state consumer protection laws and failed to meet health and safety standards governing nursing homes. An attorney for Extendicare maintained that the company takes safety very seriously at its homes.

For more information, click HERE.

July 31, 2008

Class Actions begin to add up.

The number of subprime-related class-action lawsuits filed during the first half of 2008 has surpassed those filed in all other areas combined, a recently released report says. Cornerstone Research and Stanford Law’s Securities Class Action Clearinghouse found that the vast majority of financial class actions filed during the first half of the year stemmed from subprime issues. The report also notes that the median loss leading to these class actions was $243 million and that losses haven’t been so high since the flurry of class actions between 2000 and 2002.

For more information, see HERE.

You can read the report HERE.